Latest News for Genscript Biotech Stock (OTC:GNNSF)

GenScript Biotech is a China-based provider of life science research services and products. it is known for its gene synthesis capabilities, a widely used service by academics, biotech companies, and pharmaceutical companies around the world. Its business lines include life science research services and products, biologics development services under its ProBio brand, and industrial enzymes under its Bestzyme brand. Finally, it owns 57.1% of Nasdaq-listed Legend Biotech, whose key pipeline asset is a BCMA-targeting CAR-T treatment for multiple myeloma. The company estimates that more than two-thirds of GenScript's valuation is from its ownership stake in Legend.

GENSCRIPT BIOTECH CRP ORD by Genscript Biotech Corp

Genscript Biotech Corp

RBC Capital analyst Walter Spracklin maintains Waste Management (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WM#NYSE">WM</a>) with a Sector Perform and raises the price target from $211 to $215.

News

Price Target

Analyst Ratings

RBC Capital Maintains Sector Perform on Waste Management, Raises Price Target to $215

A former senator from North Dakota, Heidi Heitkamp, expressed skepticism on the Joe Biden-led administration&#8217;s proposed 44% capital gains tax, stating it has no chance of passing.
What Happened: President Biden&#8217;s proposal to increase the capital gains rate to 44.6% in the Fiscal Year 2025 Budget has sparked significant discussion.
The main proposal is to raise the long-term capital gains and qualified dividends rates to 37% for taxpayers with taxable income above $1 million, Forbes <a href="https://www.forbes.com/newsletters/andrewleahey/2024/04/24/biden-capital-gains-rate-proposal-446/?sh=150d2081ff64">reported</a>. The 44.6% figure would only apply if an additional proposal to increase the net investment income tax rate by 1.2 percentage points for income above $400,000 is also approved.
Therefore, the 44.6% rate is not a blanket increase but would only affect individuals with taxable income above $1 million and investment income above $400,000. This is a strategic policy maneuver, focusing on high earners rather than small-business owners.
The policy aims to level the playing field between high ordinary income and investment income earners.
However, on Thursday, Heitkamp expressed her doubts about the proposal during CNBC&#8217;s &#8220;Last Call,&#8221; calling it &#8220;a political document.&#8221;
"He wants to make the point that he's advocating for higher taxes on billionaires. He did this in this document. But there's no chance this is going to pass,&#8221; she said.
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">"There's no chance this is going to pass," says <a href="https://twitter.com/HeidiHeitkamp?ref_src=twsrc%5Etfw">@HeidiHeitkamp</a> on the Biden Administration proposing a 44% capital gains tax. "President Biden wants to make the point that he's calling for higher taxes on billionaires." <a href="https://t.co/Hp3tG1bvBw">pic.twitter.com/Hp3tG1bvBw</a>
&mdash; Last Call (@LastCallCNBC) <a href="https://twitter.com/LastCallCNBC/status/1783641319232929796?ref_src=twsrc%5Etfw">April 25, 2024</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
See Also: <a href="https://www.benzinga.com/news/earnings/24/04/38424840/us-stocks-brace-for-negative-start-amid-tech-earnings-disappointments-caution-ahead-of-data-worst-o?itm_source=parsely-api" target="_blank" rel="noreferrer noopener">Meta, IBM Drag Nasdaq Futures Lower: What&#8217;s Driving Premarket Action</a>
Why It Matters: The Biden administration has been pushing for higher taxes on the ultra-rich, a move that has been met with mixed reactions. Last year, Democratic representatives reintroduced a <a href="https://www.benzinga.com/government/23/12/36078017/billionaires-tax-bill-returns-to-congress-as-supreme-court-debates-whether-it-may-be-unconstitutiona">Biden-backed bill</a> that seeks to issue a levy of 25% on the wealthiest Americans, including unrealized gains on stocks, bonds, and real estate. The legislation, if passed, could reduce the fiscal deficit by $3 trillion over ten years.
Notably, some billionaires, including Warren Buffett, <a href="https://www.benzinga.com/personal-finance/24/04/38319480/warren-buffett-wants-higher-taxes-for-the-ultra-rich-including-himself-says-my-friends-and-i-hav">chairman of Berkshire Hathaway Inc.</a> have publicly supported higher taxes on the super-rich. Buffett has previously criticized Congress&#8217;s leniency towards billionaires and called for a more equitable tax policy.
Read Next: <a href="https://www.benzinga.com/news/earnings/24/04/38374783/wall-street-set-to-open-higher-as-tesla-to-kick-off-magnificent-7-earnings-why-this-analyst-thinks-?itm_source=parsely-api" target="_blank" rel="noreferrer noopener">S&amp;P 500, Nasdaq Futures Climb Higher: Will Tesla Earnings Spark Rally Or Retreat?</a>
Photo via Shutterstock
<div style="font-family: 'Lato', sans-serif">
<div>
<hr style="border: 0;height: 5px;background: #225aa9" />
<div style="background-color: #f5f5f5;background-position: center;background-size: cover;justify-content: center"></div>

 Engineered by Benzinga Neuro, Edited by 
 <a href="https://www.benzinga.com/topic/Pooja-Rajkumari" target="_blank" rel="noopener" style="color: #225aa9;text-decoration: none">Pooja Rajkumari</a> 
 
 
<hr style="border: 0;height: 1px;background: #225aa9" />

 The GPT-4-based Benzinga Neuro content generation system exploits the extensive Benzinga Ecosystem, including native data, APIs, and more to create comprehensive and timely stories for you. 
 <a href="https://www.benzinga.com/author/benzinga-neuro" target="_blank" rel="noopener" style="color: #225aa9;text-decoration: none">Learn more.</a>
 
<hr style="border: 0;height: 5px;background: #225aa9" />
 </div>
</div>

Analyst Color

Government

Macro Economic Events

Regulations

Economics

General

Former Democratic Senator Says Biden's New Capital Gains Tax Proposal Aimed At Billionaires Has 'No Chance' Of Passing

Baird analyst Michael Halloran maintains A.O. Smith (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AOS#NYSE">AOS</a>) with a Neutral and raises the price target from $86 to $92.

Baird Maintains Neutral on A.O. Smith, Raises Price Target to $92

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our <a href="https://www.benzinga.com/analyst-ratings/">analyst ratings page</a>.
<ul>
<li>Goldman Sachs raised the price target for Microsoft Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSFT#NASDAQ">MSFT</a>) from $450 to $515. Goldman Sachs analyst Kash Rangan maintained a Buy rating. Microsoft shares fell 2.5% to close at $399.04 on Thursday. <a href="https://www.benzinga.com/quote/MSFT/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Raymond James boosted the price target for Kratos Defense &amp; Security Solutions, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KTOS#NASDAQ">KTOS</a>) from $20 to $27. Raymond James analyst Brian Gesuale upgraded the stock from Outperform to Strong Buy. Kratos Defense &amp; Security shares fell 2.8% to close at $17.28 on Thursday. <a href="https://www.benzinga.com/quote/KTOS/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Mizuho lowered Intel Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INTC#NASDAQ">INTC</a>) price target from $55 to $45. Mizuho analyst Vijay Rakesh maintained a Buy rating. Intel shares rose 1.7% to close at $35.11 on Thursday. <a href="https://www.benzinga.com/quote/INTC/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Needham raised the price target for Plexus Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PLXS#NASDAQ">PLXS</a>) from $107 to $114. Needham analyst James Ricchiuti maintained a Buy rating. Plexus shares rose 3.6% to close at $99.09 on Thursday. <a href="https://www.benzinga.com/quote/PLXS/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>B of A Securities cut Hertz Global Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HTZ#NASDAQ">HTZ</a>) price target from $9 to $3. B of A Securities analyst John Babcock downgraded the stock from Neutral to Underperform. Hertz Global shares fell 19.3% to close at $4.68 on Thursday. <a href="https://www.benzinga.com/quote/HTZ/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Citigroup increased Alphabet Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOOGL#NASDAQ">GOOGL</a>) price target from $168 to $190. Citigroup analyst Ronald Josey maintained a Buy rating. Alphabet shares fell 2% to close at $156.00 on Thursday. <a href="https://www.benzinga.com/quote/GOOGL/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Stifel raised the price target for Caterpillar Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CAT#NYSE">CAT</a>) from $293 to $350. Stifel analyst Stanley Elliott downgraded the stock from Buy to Hold. Caterpillar shares fell 7% to close at $338.00 on Thursday. <a href="https://www.benzinga.com/quote/CAT/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Oppenheimer raised Tyler Technologies, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TYL#NYSE">TYL</a>) price target from $480 to $500. Oppenheimer analyst Ken Wong maintained an Outperform rating. Tyler Technologies shares rose 9.3% to close at $458.07 on Thursday. <a href="https://www.benzinga.com/quote/TYL/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>JP Morgan boosted Dow Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DOW#NYSE">DOW</a>) price target from $55 to $61. JP Morgan analyst Jeffrey Zekauskas upgraded the stock from Neutral to Overweight. Dow shares fell 1% to close at $56.44 on Thursday. <a href="https://www.benzinga.com/quote/DOW/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Baird boosted Tractor Supply Company (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSCO#NASDAQ">TSCO</a>) price target from $260 to $285. Baird analyst Justin Kleber maintained an Outperform rating. Tractor Supply shares rose 2.8% to close at $265.26 on Thursday. <a href="https://www.benzinga.com/quote/TSCO/analyst-ratings">See how other analysts view this stock</a>.</li>
</ul>
Check This Out: <a href="https://www.benzinga.com/news/24/04/38454731/intel-reports-weak-sales-joins-boyd-gaming-atlassian-and-other-big-stocks-moving-lower-in-fridays-pr">Intel Reports Weak Sales, Joins Boyd Gaming, Atlassian And Other Big Stocks Moving Lower In Friday&#8217;s Pre-Market Session</a>

Markets

Trading Ideas

GOOGL

INTC

KTOS

MSFT

PLXS

TSCO

Microsoft To Rally Over 29%? Here Are 10 Top Analyst Forecasts For Friday

Piper Sandler (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PIPR#NYSE">PIPR</a>) reported quarterly earnings of $2.79 per share which beat the analyst consensus estimate of $2.19 by 27.4 percent. This is a 18.72 percent increase over earnings of $2.35 per share from the same period last year. The company reported quarterly sales of $343.056 million which beat the analyst consensus estimate of $314.961 million by 8.92 percent. This is a 15.16 percent increase over sales of $297.905 million the same period last year.

Earnings

Earnings Beats

PIPR

Piper Sandler Q1 2024 Adj EPS $2.79 Beats $2.19 Estimate, Sales $343.056M Beat $314.961M Estimate

Baird analyst Luke Junk maintains Allison Transmission (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ALSN#NYSE">ALSN</a>) with a Neutral and raises the price target from $84 to $87.

ALSN

Baird Maintains Neutral on Allison Transmission, Raises Price Target to $87

Sobi&#xAE; today announced the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency has issued a positive opinion recommending approval of efanesoctocog alfa, for the treatment and prevention of bleeds and perioperative prophylaxis in haemophilia A. Efanesoctocog alfa is a once-weekly and high-sustained factor VIII replacement therapy for patients of all ages and any disease severity.
Efanesoctocog alfa provides children, adolescents and adults with normal to near-normal factor VIII activity levels (above 40%) for a significant part of the week with once-weekly dosing, reaching trough levels of 15% in adults and adolescents at day 7. This results in significantly improved protection from bleeds compared to existing factor VIII prophylaxis. The CHMP positive opinion will now be submitted to the European Commission for a marketing authorisation decision.
"Today's announcement marks a major milestone in haemophilia care and moves us one step closer to bringing efanesoctocog alfa to patients in the EU. Efanesoctocog alfa sustains high factor VIII activity levels throughout the week, giving patients confidence in the protection it can provide to prevent bleeds, manage surgery, and resolve bleeds. With the potential to significantly improve treatment outcomes and quality of life for people living with haemophilia A, we are excited about the positive impact this treatment could have around the world," said Lydia Abad-Franch, MBA, Head of Research, Development, and Medical Affairs, and Chief Medical Officer at Sobi.
Haemophilia A is a rare, lifelong genetic condition in which the body does not produce enough, or makes dysfunctional, factor VIII – a protein that is essential for blood clotting. It occurs in about one in 5,000 male births annually, and more rarely in females. People with haemophilia can experience bleeding episodes that can cause pain, irreversible joint damage and life-threatening haemorrhages. Clinical outcomes have improved over time thanks to significant advances in the treatment options available, however important unmet clinical and social needs still exist for those living with the condition.
The recommendation from the CHMP is based on the results from the pivotal phase 3 studies: XTEND-1 in adults and adolescents and XTEND-Kids in children, which evaluated the efficacy and safety of efanesoctocog alfa. These studies demonstrated that once-weekly efanesoctocog alfa prophylaxis (50 IU/kg) provided significant bleed protection (mean ABR &lt;1 and 80-88% of patients free from spontaneous bleeds) in people with severe haemophilia A of any age. The data also showed substantial improvement in joint health, physical health, pain and overall quality of life when comparing week 52 and baseline measurements.1 No factor VIII inhibitors were observed in the efanesoctocog alfa clinical program.
Efanesoctocog alfa was first approved in the US in February 2023 by the US Food and Drug Administration (FDA). The FDA previously granted&nbsp;efanesoctocog alfa Breakthrough Therapy designation in May 2022 — the first factor VIII therapy to receive this designation, Fast Track designation in February 2021, and Orphan Drug designation in 2017.

Biotech

Sobi Receives Positive CHMP Opinion Recommending Approval Of Efanesoctocog Alfa For Once-Weekly Treatment Of Haemophilia A

<h3>Gainers</h3>
<ul>
<li>Worksport (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WKSP#NASDAQ">WKSP</a>) shares increased by 16.5% to $0.48 during Friday's pre-market session. The market value of their outstanding shares is at $11.5 million. </li>
<li>Vision Marine (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VMAR#NASDAQ">VMAR</a>) stock rose 11.9% to $0.63. The company's market cap stands at $7.6 million. </li>
<li>Skechers USA (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SKX#NYSE">SKX</a>) stock increased by 10.5% to $65.0. The company's market cap stands at $10.1 billion. As per the press release, Q1 earnings came out yesterday. </li>
<li>SRIVARU Holding (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SVMH#NASDAQ">SVMH</a>) stock increased by 10.33% to $0.2. The market value of their outstanding shares is at $6.4 million. </li>
<li>Zapp Electric Vehicles (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZAPP#NASDAQ">ZAPP</a>) stock moved upwards by 9.79% to $3.25. The market value of their outstanding shares is at $10.1 million. </li>
<li>Jeffs Brands (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JFBR#NASDAQ">JFBR</a>) shares increased by 9.2% to $0.28. The market value of their outstanding shares is at $1.6 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Boyd Gaming (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BYD#NYSE">BYD</a>) stock decreased by 9.8% to $56.76 during Friday's pre-market session. The market value of their outstanding shares is at $5.4 billion. As per the news, the Q1 earnings report came out yesterday. </li>
<li>Uxin (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UXIN#NASDAQ">UXIN</a>) stock fell 8.72% to $1.78. The company's market cap stands at $334.5 million. As per the press release, Q3 earnings came out yesterday. </li>
<li>Connexa Sports Techs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/YYAI#NASDAQ">YYAI</a>) shares decreased by 7.16% to $0.78. The market value of their outstanding shares is at $144.0 million. </li>
<li>Kaixin Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KXIN#NASDAQ">KXIN</a>) shares declined by 5.59% to $0.12. The company's market cap stands at $3.2 million. </li>
<li>Foresight Autonomous (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FRSX#NASDAQ">FRSX</a>) shares decreased by 5.56% to $1.02. The market value of their outstanding shares is at $15.6 million. </li>
<li>U Power (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UCAR#NASDAQ">UCAR</a>) shares declined by 5.3% to $5.01. The market value of their outstanding shares is at $12.3 million. 
See Also: <a href="http://www.benzinga.com/money/best-consumer-cyclical-stocks/" title="www.benzinga.com/money/best-consumer-cyclical-stocks/">www.benzinga.com/money/best-consumer-cyclical-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Movers

FRSX

JFBR

KXIN

SVMH

UCAR

UXIN

VMAR

WKSP

Connexa Sports Technologies Inc. - Common Stock

YYAI

ZAPP

12 Consumer Discretionary Stocks Moving In Friday's Pre-Market Session

<h3>Gainers</h3>
<ul>
<li>Tevogen Bio Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TVGN#NASDAQ">TVGN</a>) shares rose 75.3% to $1.49 during Friday's pre-market session. The company's market cap stands at $245.2 million. </li>
<li>Cryo-Cell International (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/CCEL#AMEX">CCEL</a>) shares increased by 27.94% to $9.98. The market value of their outstanding shares is at $80.8 million. </li>
<li>Fresh2 Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FRES#NASDAQ">FRES</a>) shares moved upwards by 18.33% to $0.71. The market value of their outstanding shares is at $17.4 million. </li>
<li>Inspire Veterinary (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IVP#NASDAQ">IVP</a>) shares rose 16.79% to $0.04. The company's market cap stands at $3.9 million. </li>
<li>Moleculin Biotech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MBRX#NASDAQ">MBRX</a>) stock increased by 15.82% to $4.99. The market value of their outstanding shares is at $11.1 million. </li>
<li>Genprex (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GNPX#NASDAQ">GNPX</a>) stock increased by 11.47% to $2.36. The company's market cap stands at $4.5 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Processa Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PCSA#NASDAQ">PCSA</a>) shares fell 15.6% to $2.05 during Friday's pre-market session. The market value of their outstanding shares is at $5.8 million. </li>
<li>SCWorx (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WORX#NASDAQ">WORX</a>) shares decreased by 15.58% to $2.33. The market value of their outstanding shares is at $2.8 million. </li>
<li>Nuwellis (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NUWE#NASDAQ">NUWE</a>) shares declined by 13.85% to $0.25. The market value of their outstanding shares is at $1.6 million. </li>
<li>Aclarion (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACON#NASDAQ">ACON</a>) stock fell 12.79% to $0.34. The company's market cap stands at $2.4 million. </li>
<li>Vincerx Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VINC#NASDAQ">VINC</a>) shares decreased by 12.13% to $0.79. The company's market cap stands at $16.8 million. </li>
<li>Protagenic Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PTIX#NASDAQ">PTIX</a>) shares decreased by 12.03% to $1.38. The company's market cap stands at $6.1 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

ACON

CCEL

FRES

GNPX

MBRX

NUWE

PCSA

PTIX

TVGN

VINC

WORX

12 Health Care Stocks Moving In Friday's Pre-Market Session

<h3>Gainers</h3>
<ul>
<li>Pineapple Energy (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PEGY#NASDAQ">PEGY</a>) stock moved upwards by 52.2% to $0.08 during Friday's pre-market session. The company's market cap stands at $5.0 million. </li>
<li>Freight Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FRGT#NASDAQ">FRGT</a>) stock moved upwards by 46.65% to $1.34. The company's market cap stands at $3.2 million. </li>
<li>Earlyworks Co (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ELWS#NASDAQ">ELWS</a>) stock rose 27.34% to $0.94. The company's market cap stands at $14.0 million. </li>
<li>GrafTech International (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EAF#NYSE">EAF</a>) stock moved upwards by 15.52% to $1.86. The market value of their outstanding shares is at $477.7 million. The company's, Q1 earnings came out today. </li>
<li>Exponent (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EXPO#NASDAQ">EXPO</a>) stock increased by 12.57% to $89.7. The market value of their outstanding shares is at $4.5 billion. As per the press release, Q1 earnings came out yesterday. </li>
<li>Jet AI (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JTAI#NASDAQ">JTAI</a>) shares moved upwards by 7.84% to $0.76. The company's market cap stands at $9.2 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Saia (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SAIA#NASDAQ">SAIA</a>) shares decreased by 14.4% to $465.0 during Friday's pre-market session. The market value of their outstanding shares is at $12.3 billion. The company's, Q1 earnings came out today. </li>
<li>Safe &amp; Green Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SGBX#NASDAQ">SGBX</a>) stock fell 10.19% to $0.2. The market value of their outstanding shares is at $3.6 million. </li>
<li>Zoomcar Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZCAR#NASDAQ">ZCAR</a>) shares decreased by 8.84% to $0.32. The company's market cap stands at $20.8 million. </li>
<li>Northann (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/NCL#AMEX">NCL</a>) shares fell 8.59% to $0.43. The company's market cap stands at $9.0 million. </li>
<li>Intelligent Living (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ILAG#NASDAQ">ILAG</a>) stock fell 6.95% to $0.52. The company's market cap stands at $9.4 million. </li>
<li>Swvl Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SWVL#NASDAQ">SWVL</a>) stock declined by 6.71% to $11.34. The market value of their outstanding shares is at $77.0 million. 
See Also: <a href="http://www.benzinga.com/money/best-industrials-stocks/" title="www.benzinga.com/money/best-industrials-stocks/">www.benzinga.com/money/best-industrials-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

ELWS

EXPO

FRGT

ILAG

JTAI

Nuveen Insured California Premium Fund Ii

PEGY

SAIA

SGBX

SWVL

ZCAR

12 Industrials Stocks Moving In Friday's Pre-Market Session

<h3>Gainers</h3>
<ul>
<li>AppFolio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APPF#NASDAQ">APPF</a>) stock moved upwards by 10.8% to $240.0 during Friday's pre-market session. The company's market cap stands at $8.6 billion. As per the news, the Q1 earnings report came out yesterday. </li>
<li>Ostin Technology Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OST#NASDAQ">OST</a>) stock rose 10.21% to $0.45. The market value of their outstanding shares is at $7.5 million. </li>
<li>Infobird Co (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IFBD#NASDAQ">IFBD</a>) stock moved upwards by 8.13% to $3.99. The market value of their outstanding shares is at $5.3 million. </li>
<li>Hitek Global (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HKIT#NASDAQ">HKIT</a>) stock rose 7.74% to $1.53. The market value of their outstanding shares is at $22.0 million. </li>
<li>Rubicon Technologies (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RBT#NYSE">RBT</a>) stock moved upwards by 7.11% to $0.42. The company's market cap stands at $22.0 million. </li>
<li>T Stamp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IDAI#NASDAQ">IDAI</a>) stock rose 6.57% to $0.81. The market value of their outstanding shares is at $8.5 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Spectaire Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SPEC#NASDAQ">SPEC</a>) stock decreased by 8.7% to $0.52 during Friday's pre-market session. The market value of their outstanding shares is at $8.7 million. </li>
<li>MMTEC (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MTC#NASDAQ">MTC</a>) shares declined by 8.26% to $2.89. The market value of their outstanding shares is at $575.5 million. </li>
<li>Intel (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INTC#NASDAQ">INTC</a>) shares decreased by 7.72% to $32.4. The company's market cap stands at $137.9 billion. As per the press release, Q1 earnings came out yesterday. </li>
<li>ARB IOT Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARBB#NASDAQ">ARBB</a>) stock fell 7.41% to $1.0. The company's market cap stands at $26.4 million. </li>
<li>SMX (Security Matters) (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SMX#NASDAQ">SMX</a>) shares declined by 5.77% to $0.15. The company's market cap stands at $4.9 million. </li>
<li>Atlassian (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TEAM#NASDAQ">TEAM</a>) stock declined by 5.76% to $186.99. The company's market cap stands at $48.5 billion. As per the press release, Q3 earnings came out yesterday. 
See Also: <a href="http://www.benzinga.com/money/tech-stocks/" title="www.benzinga.com/money/tech-stocks/">www.benzinga.com/money/tech-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

APPF

ARBB

HKIT

IDAI

IFBD

SPEC

TEAM

12 Information Technology Stocks Moving In Friday's Pre-Market Session

Rosenblatt analyst Andrew Bond maintains Nasdaq (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NDAQ#NASDAQ">NDAQ</a>) with a Buy and lowers the price target from $82 to $76.

NDAQ

Rosenblatt Maintains Buy on Nasdaq, Lowers Price Target to $76

WIIM

Skechers USA shares ares trading higher after the company reported better-than-expected Q1 financial results.

Additionally, based on the Company&#39;s current forecast for light vehicle production for calendar year 2025, the Company still expects calendar year 2025 revenue of approximately&nbsp;$2.65&nbsp;-&nbsp;$2.75 billion.

Guidance

GNTX

Gentex Continues To See 2024 Revenue Of $2.45B-$2.55B, Est $2.516B

– Additional Data in Pregnant Adults Who Are Virologically Suppressed Reinforce Safety and Tolerability Profile of Biktarvy in Broad Range of People With HIV –
– Perinatal Guidelines Recognize Biktarvy as Alternative Regimen for Use During Pregnancy and for Those Trying to Conceive –
Gilead Sciences, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GILD#NASDAQ">GILD</a>) today announced the U.S. Food and Drug Administration (FDA) approved an updated label with additional data reinforcing the safety and efficacy profile of Biktarvy&#xAE; (bictegravir 50 mg/emtricitabine 200 mg/tenofovir alafenamide 25 mg tablets, B/F/TAF) to treat pregnant people with HIV-1 (PWH) with suppressed viral loads. These additional data stem from Study 5310, which evaluated the pharmacokinetics, safety and efficacy of Biktarvy in pregnant PWH who have suppressed viral loads and no known resistance to any components of Biktarvy in their second and third trimesters and through a median of 16 weeks postpartum. This update makes Biktarvy the only second-generation integrase strand transfer inhibitor (INSTI)-based single-tablet regimen (STR) with in-label clinical trial data and FDA approval in virologically suppressed adults who are pregnant. The U.S. Department of Health and Human Services (DHHS) perinatal guidelines recognize Biktarvy as having sufficient data to support being recommended as an alternative complete regimen for use in pregnancy and for people who are trying to conceive. Additionally, guidelines recommend continuing Biktarvy for PWH already on treatment who are virologically suppressed and tolerating treatment well who may become pregnant.
"This label update marks an important milestone for Biktarvy, reinforcing its efficacy profile for pregnant PWH, an often understudied and most vulnerable community in clinical research," said Jared Baeten, MD, PhD, Vice President, HIV Clinical Development, Gilead Sciences. "Not only is Biktarvy an alternative regimen for use in pregnancy, but people of childbearing potential can also remain on Biktarvy if they become pregnant. We continue to keep people at the center of our tireless commitment to HIV treatment research and development so that our medicines address the needs of the broad range of communities that we serve."
The updated label now includes additional data from Study 5310, a Phase 1b, open-label, single-arm, multicenter clinical trial evaluating the pharmacokinetics, safety and efficacy of Biktarvy in pregnant PWH who were virologically suppressed (HIV-1 RNA &lt; 50 copies/mL) and had no known resistance to the components of Biktarvy. Participants were administered Biktarvy once daily from the second or third trimester through postpartum. Lower plasma exposures of Biktarvy were observed during pregnancy as compared to postpartum; all 32 participants who completed the study maintained viral suppression during pregnancy, at delivery and through week 18 postpartum. The median CD4+ cell count at baseline was 558 cells/μL, and the median change in CD4+ cell count from baseline to week 12 postpartum was 159 cells/μL. All 29 newborn participants had negative/nondetectable HIV-1 PCR results at birth and/or at four to eight weeks post birth. Further, the study did not identify any new safety or tolerability concerns for people who use Biktarvy during pregnancy and postpartum as the overall incidence and types of adverse events observed were consistent with those expected for the population studied.
This label update marks a significant milestone in Gilead's efforts to address the individual needs of all people impacted by HIV, as these data can help to provide assurance for people of childbearing potential to remain on Biktarvy if they were to become pregnant. The Biktarvy label was also updated in February 2024 to align with Centers for Disease Control and Prevention (CDC) guidance on breastfeeding, which encourages a dialogue between a person and their healthcare provider regarding breastfeeding.
"As an OB-GYN and a longtime women's health advocate, I'm incredibly passionate about helping end health disparities among women, and especially Black women who are disproportionately impacted by HIV," said Yolanda M. Lawson, MD, President, National Medical Association. "I'm encouraged by the tremendous progress made in personalizing HIV treatment over the years, including this milestone that further supports the safety profile of Biktarvy use during pregnancy. Together, we can help bring all PWH the care they need, including those who are or may become pregnant, so they can continue to live longer, healthier lives while on HIV treatment."
"These additional data can help to better inform treatment decisions between pregnant PWH and their providers and mark an incredible step forward in addressing the unique needs PWH have when they are pregnant or planning to become pregnant," said William R. Short, MD, Associate Professor of Medicine, Perelman School of Medicine at the University of Pennsylvania. "As experts in perinatal care, we will continue to recommend ways pregnant PWH can maintain undetectable viral loads so they can stay healthy and prevent transmission to their baby."
Please see below for U.S. Indications and Important Safety Information for Biktarvy, including Boxed Warning.
There is no cure for HIV or AIDS.

GILD

FDA Approves Biktarvy Label Update With Data For Pregnant Adults With HIV; Perinatal Guidelines Recognize Biktarvy As Alternative Regimen For Use During Pregnancy And For Those Trying To Conceive

Exponent shares are trading higher after the company reported better-than-expected Q1 financial results.

Baird analyst Eric Coldwell maintains Laboratory Corp (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LH#NYSE">LH</a>) with a Outperform and lowers the price target from $255 to $244.

Laboratory Corporation Of America Holdings

Baird Maintains Outperform on Laboratory Corp, Lowers Price Target to $244

Vincerx Pharma shares are trading lower after the company announced a proposed underwritten public offering of common stock and warrants.

ROKU

Roku shares are trading lower, reversing after gaining late Thursday on Q1 earnings.

iClick Interactive Asia Group Limited ("iClick" or the "Company") (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ICLK#NASDAQ">ICLK</a>), a leading enterprise and marketing cloud platform in China that empowers worldwide brands with full-stack consumer lifecycle solutions, today announced the termination of the previously announced agreement and plan of merger, dated as of November 24, 2023 (the "Merger Agreement"), by and among the Company, TSH Investment Holding Limited (the "Parent") and TSH Merger Sub Limited (the "Merger Sub").
&nbsp;
On March 29, 2024, the Company delivered to the Parent a notice (the "Closing Notice") confirming the satisfaction of the closing conditions under the Merger Agreement (other than those conditions that by their nature are to be satisfied by actions taken at the Closing as defined below) and that the Company is ready, willing and able to consummate the closing contemplated under the Merger Agreement (the "Closing").&nbsp; Since the delivery of the Closing Notice, the Company has been communicating and cooperating with the Parent, Merger Sub and their representatives towards the Closing, but the Parent and Merger Sub have failed to complete the Closing within ten (10) Business Days following the delivery date of the Closing Notice pursuant to Section 8.03(b) of the Merger Agreement.&nbsp;
On April 26, 2024, the Company (acting upon the recommendation of the Special Committee) sent a notice of termination to the Parent and the Merger Sub pursuant to Section 8.03(b) of the Merger Agreement, notifying the Parent and the Merger Sub that the Company is exercising its right to terminate the Merger Agreement pursuant to Section 8.03(b) of the Merger Agreement and demanding the Parent to pay the US$1,800,000 termination fee pursuant to Section 8.06(b) of the Merger Agreement by May 9, 2024.&nbsp; &nbsp;As a result of the termination of the Merger Agreement, the proposed merger will not be completed.&nbsp;

Contracts

ICLK

iClick Interactive Asia Group Limited Announces Termination Of Merger Agreement

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
Biology is the study of life. And synthetic biology is the creation of new life for new purposes. Ever since the Green Revolution of the 1970s, synthetic biology has allowed us to make new crops, drugs, and additives for profit and to make the world a better place.
But the true promise of synthetic biology is still to come. Many drugs and products are still made chemically, but can instead be made with synthetic biology. Many novel organisms can be used for research or industrial purposes. And the rewards of wealth still await the investors who can understand the science and finance of the best synthetic biology stocks to buy now.
It&rsquo;s also critical to understand the breadth of synthetic biology in today&rsquo;s market. Synthetic biology is so much more than DNA stocks. It includes hundreds of companies making new organisms for new purposes. It has spread across nearly every industry sector that uses biology at all. Thus, the synthetic biology revolution is not a small part of the stock market anymore.
Although synthetic biology stocks had a poor 2022, a new year is still ahead, and the future looks bright for the industry. Don&rsquo;t write all synthetic biology stocks off just because the <a href="https://investorplace.com/stock-types/meme-stocks/">meme stocks</a> crashed and burned! Here are 3 DNA stocks to buy for the synthetic biology revolution.

<a href="https://investorplace.com/stock-quotes/txg-stock-quote/">TXG</a>
10x Genomics
$52.64
<a href="https://investorplace.com/stock-quotes/crl-stock-quote/">CRL</a>
Charles River Laboratories
$191.24
<a href="https://investorplace.com/stock-quotes/twst-stock-quote/">TWST</a>
Twist Bioscience
$11.95

<h2>10x Genomics (TXG)</h2>
<div><img src="https://investorplace.com/wp-content/uploads/2020/03/gene_editing_a_1600-300x169.jpg" alt="Gene editing stocks: a concept image of a hand holding a pair of tweezers that is pulling a section off of a dna strand" width="300" height="169"><div>Source: vxhal/ShutterStock.com</div></div>
10x Genomics (NASDAQ:<a href="https://investorplace.com/stock-quotes/txg-stock-quote/">TXG</a>) specializes in the study of single cell genomics. Although all the cells in our body contain the same DNA, that DNA is stored, read, and used differently in different cells. That is what allows muscle cells to develop and act differently than nerve cells. And 10x Genomics gives researchers a window in the world of each individual cell in a body.
10x Genomics allows scientists to sequence the DNA or RNA of millions of cells across multiple different dimensions simultaneously. That allows researchers to study how cells react to drugs across multiple avenues. It also allows researchers to spot why a drug may work for some cells and not others, as well as how to fix that.
10x Genomics stock fell hard during the biotech crash of 2022, but has been recovering since then. Their <a href="https://s28.q4cdn.com/592666581/files/doc_financials/2023/q1/c15e0c95-b939-4312-9c71-e37e7211b314.pdf">Q1 2023 earnings</a> show a company with growing revenue, and the cash on hand to continue losing money at their current pace for a while yet.
Genetic sequencing is only going to get more important as drug screens become more and more complex. Scientists are now making completely new cells, of multiple types, to assist in studying how drugs will react inside our bodies. And every cell is tested across multiple genetic avenues. More and more drug companies are entering the world of Big Genomics, and that&rsquo;s exactly why they&rsquo;ll be working with 10x Genomics.

<h2>Charles River Laboratories (CRL)</h2>
<div><img src="https://investorplace.com/wp-content/uploads/2021/08/laboratory-scientist-1600-300x169.jpg" alt="scientist wearing virtual reality headset interacts with futuristic holographic interface showing neurological data" width="300" height="169"><div>Source: Gorodenkoff / Shutterstock</div></div>
Charles River Laboratories (NYSE:<a href="https://investorplace.com/stock-quotes/crl-stock-quote/">CRL</a>) is a Contract Research Organization (CRO) that specializes in making other companies&rsquo; synthetic biology dreams into a reality. The company provides services for <a href="https://www.criver.com/products-services/research-models-services/genetically-engineered-model-services?region=3601">making and testing</a> any new genetically modified species to suit a client&rsquo;s needs. Scientists often want to study an animal that is specifically tailored to model a human disease or condition. Charles River&rsquo;s technology allows for more accurate results when performing drug screens against that condition than when using naturally-evolved animals.
Charles River also sells its contract research services to other synthetic biology companies. Many companies have a will, but not the way to perform complex synthetic biology. Charles Rivers has the synthetic biology expertise to help those companies. This provides a niche, allowing the company to profit off the entire synthetic biology industry, rather than being tied down to a single drug or pipeline.
It may seem unglamourous, but a CRL stock is a much safer play than investing directly in a smaller synthetic biology company. Whenever someone invents a new drug, they&rsquo;ll need someone to help them screen it, make it at scale, and test it for purity. Charles river is that someone.
The company&rsquo;s <a href="https://ir.criver.com/static-files/8ae49c45-37d8-4184-94c9-74cf511974a0">Q1 2023 earnings</a> highlighted $4 billion in revenue and $489 million in net income. Demand for the company&rsquo;s services will only increase with the continued rise of synthetic biology. It&rsquo;s best to get in early in cases such as this.

<h2>Twist Bioscience (TWST)</h2>
<div><img src="https://investorplace.com/wp-content/uploads/2022/11/twst1600-300x169.png" alt="Scientific handling a light microscope examines a laboratory sample for pharmaceutical bioscience research. Concept of science, laboratory and study of diseases. Twist Biosciences (TWST)" width="300" height="169"><div>Source: dhvstockphoto / Shutterstock.com</div></div>
Among DNA stocks, Twist Bioscience (NASDQ:<a href="https://investorplace.com/stock-quotes/twst-stock-quote/">TWST</a>) stands above the rest in terms of price. It offers to sell DNA at a cost as low as <a href="https://www.twistbioscience.com/products/genes">7 cents</a> per base pair, far below competitors like Genscript (OTCMKTS:<a href="https://investorplace.com/stock-quotes/gnnsf-stock-quote/">GNNSF</a>) and Azenta (NASDAQ:<a href="https://investorplace.com/stock-quotes/azta-stock-quote/">AZTA</a>). DNA is the fundamental ingredient of synthetic biology. And Twist is positioned to sell more of it than anyone else.
DNA may seem like simple stuff, but don&rsquo;t be fooled. For any single new organism that gets commercialized, there were thousands of organisms that had to be created and tested. And for each organism created, a specific genetic library must be purchased to create it. Demand for novel DNA will continue to increase as more synthetic biology companies are created. And Twist&rsquo;s price means it can sell to all of them.
Like other synthetic biology companies, Twist&rsquo;s stock took a beating in 2022. However, unlike many of its peers, the beatings haven&rsquo;t let up in 2023. Still, the company&rsquo;s <a href="https://investors.twistbioscience.com/static-files/ab61e0e9-9226-4307-89ed-0d667252d936">Q1 2023 earnings</a> have given reason to be hopeful. With 25% revenue growth year-over-year ($48 million to $60 million), they&rsquo;re making headway. And with $315 million in cash and cash equivalents with $61 million in net loss, they can keep this burn rate for some time yet.
While Twist may be a speculative play, they&rsquo;ve got the runway needed to fly. And that makes Twist one of the most enticing synthetic biology companies of 2023.
On the date of publication, John Blankenhorn did not hold (either directly or indirectly) any positions in the securities mentioned in this article. The opinions expressed in this article are those of the writer, subject to the InvestorPlace.com <a href="https://investorplace.com/corporate/investorplace-publishing-guidelines/">Publishing Guidelines</a>.
<div>
John Blankenhorn is a neuroscientist at Emory University. He has significant experience in biochemistry, biotechnology and pharmaceutical research.
</div>
<h3>More From InvestorPlace</h3>
<ul><li>
						<a href="https://investorplace.com/2022/07/little-known-apple-project/?cid=MKT639809&amp;eid=MKT653131">Buy This $5 Stock BEFORE This Apple Project Goes Live</a>
					</li>
<li>
						<a href="https://investorplace.com/2022/06/this-could-be-the-best-deal-in-the-history-of-independent-investing-research/?cid=MKT638063&amp;eid=MKT644740">The Best $1 Investment You Can Make Today</a>
					</li>
<li>
						<a href="https://investorplace.com/2023/04/one-of-the-worlds-biggest-tech-breakthroughs-could-be-happening-in-americas-heartland/?cid=MKT714907&amp;eid=MKT731269">Wall Street Titan: Here&rsquo;s My #1 Stock for 2023</a>
					</li>
<li>
						<a href="https://investorplace.com/2021/01/one-percenter-issues-urgent-warning/?cid=MKT499868&amp;eid=MKT513141">It doesn&rsquo;t matter if you have $500 or $5 million. Do this now.</a>
					</li>
</ul><div>
<div>
<div></div>
<div></div>
</div>
</div>

The post <a href="https://investorplace.com/2023/05/3-dna-stocks-to-buy-for-the-synthetic-biology-revolution/">3 DNA Stocks to Buy for the Synthetic Biology Revolution</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

3 DNA Stocks to Buy for the Synthetic Biology Revolution

GenScript Biotech Corporation (GNNSF) Q2 2023 Earnings Call Transcript

In a report released yesterday, Chris Lui from Jefferies maintained a Buy rating on Genscript Biotech (GNNSF – Research Report), with a price targe...

Jefferies Sticks to Their Buy Rating for Genscript Biotech (GNNSF)

Jefferies analyst Chris Lui maintained a Buy rating on Genscript Biotech (GNNSF – Research Report) yesterday and set a price target of HK$30.00. Th...

Jefferies Reaffirms Their Buy Rating on Genscript Biotech (GNNSF)

Week In Review: AlphaGen And ArtBio Form China-U.S. Radioligand Partnership

GenScript Biotech Corporation (GNNSF) Q4 2023 Earnings Call Transcript

Genscript Biotech GAAP EPS of -$4.53, revenue of $839.5M misses by $460.5M

Genscript Biotech GAAP EPS of -$0.045, revenue of $839.5M misses by $460.5M

GenScript Losses Shrink On Strong Growth For Cancer Cell Therapy

AZTA

GNNSF

IVBIY

IVBXF

LEGN

TWST

Genscript Biotech

Genscript Biotech, Legend Biotech USA & Janssen Research + Development & Novartis Pharmaceuticals Corp Entered Master Technology Transfer

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Latest News for Genscript Biotech Stock (OTC:GNNSF)

Friday, April 14, 2023